Welcome to our dedicated page for KYNTRA BIO SEC filings (Ticker: KYNB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kyntra Bio filings document the company's public-company governance, financial reporting, clinical-development updates, and Nasdaq listing matters. Recent 8-K reports cover results of operations and financial condition, including business updates tied to FG-3246, roxadustat, and the FG-3180 biomarker program.
The filing record also includes definitive proxy statements that disclose governance matters, executive compensation, equity awards, and shareholder voting information. Additional 8-K disclosure addresses Nasdaq continued-listing compliance, reflecting the company's capital-market and reporting obligations as a Nasdaq-listed biopharmaceutical issuer.
FibroGen Inc. Schedule 13G/A: Armistice Capital, LLC and Steven Boyd report beneficial ownership of 400,000 shares of common stock, representing 9.89% of the class as of 12/31/2025. The filing states Armistice Capital is the investment manager of Armistice Capital Master Fund Ltd., the direct holder, and that the Master Fund has the right to receive dividends or sale proceeds. Steven Boyd is identified as managing member of Armistice Capital and files jointly with the firm.
FibroGen Inc. Schedule 13G/A: Armistice Capital, LLC and Steven Boyd report beneficial ownership of 400,000 shares of common stock, representing 9.89% of the class as of 12/31/2025. The filing states Armistice Capital is the investment manager of Armistice Capital Master Fund Ltd., the direct holder, and that the Master Fund has the right to receive dividends or sale proceeds. Steven Boyd is identified as managing member of Armistice Capital and files jointly with the firm.
Kyntra Bio, Inc. reported that CEO and director Thane Wettig received a grant of stock options. On February 3, 2026, he was awarded options to purchase 60,000 shares of common stock at an exercise price of $8.50 per share, with no cash price paid for the grant itself.
The options vest in equal amounts quarterly over four years starting from February 3, 2026, and are exercisable until February 2, 2036. Following this award, Wettig beneficially owns 60,000 stock options, held directly.
Kyntra Bio, Inc. reported that CEO and director Thane Wettig received a grant of stock options. On February 3, 2026, he was awarded options to purchase 60,000 shares of common stock at an exercise price of $8.50 per share, with no cash price paid for the grant itself.
The options vest in equal amounts quarterly over four years starting from February 3, 2026, and are exercisable until February 2, 2036. Following this award, Wettig beneficially owns 60,000 stock options, held directly.
Kyntra Bio, Inc. reported an option grant to its Chief Financial Officer, David DeLucia. On 02/03/2026, he was awarded a stock option for 26,000 shares of common stock at an exercise price of $8.50 per share.
The option vests in equal amounts quarterly over four years starting on 02/03/2026. Following this grant, DeLucia beneficially owns 26,000 derivative securities directly through this option award.
Kyntra Bio, Inc. reported an option grant to its Chief Financial Officer, David DeLucia. On 02/03/2026, he was awarded a stock option for 26,000 shares of common stock at an exercise price of $8.50 per share.
The option vests in equal amounts quarterly over four years starting on 02/03/2026. Following this grant, DeLucia beneficially owns 26,000 derivative securities directly through this option award.